ALT Our partner laboratories include: · Precision Biomarker Laboratories, Los Angeles · Sapient Bioanalytics, San Diego · Ghent University Faculty of Pharmaceutical Sciences · Stanford University · University of Virginia · IARC, Lyon, France · University of Antwerp · Hasselt University · University of Manitoba · University of California Berkeley · University of California San Diego · USDA · Biocartes Life Sciences, Innsbruck, Austria · Baylor College of Medicine, Huston, TX
ALT Maternal and infant body composition was assessed using D₂O. During the 3ʳᵈ week postpartum, 3 saliva samples were taken from each subject. Infants received 1g and mothers 6g of D₂O. Saliva samples were taken at specific intervals, stored at low temperatures, and transported to the lab weekly. The D₂O concentrations were measured with FTIR spectrophotometry.
ALT BACKGROUND: Providing balanced energy–protein (BEP) supplements is a promising intervention to improve birth outcomes in low- and middle-income countries (LMICs); however, evidence is limited. We aimed to assess the efficacy of fortified BEP supplementation during pregnancy to improve birth outcomes, as compared to iron–folic acid (IFA) tablets, the standard of care. METHODS AND FINDINGS: We conducted an individually randomized controlled efficacy trial in rural Burkina Faso. Pregnant women, aged 15 to 40 years were randomly assigned to receive either fortified BEP supplements and IFA (intervention) or IFA (control). CONCLUSIONS: The MISAME-III trial did not provide evidence that fortified BEP supplementation is efficacious in reducing SGA prevalence. However, the intervention had a small positive effect on other birth outcomes. Additional maternal and biochemical outcomes need to be investigated to provide further evidence on the overall clinical relevance of BEP supplementation.
